(0.06%) 5 073.80 points
(-0.02%) 38 497 points
(0.14%) 15 718 points
(-0.53%) $82.92
(-9.05%) $1.648
(-0.36%) $2 333.60
(-0.37%) $27.26
(-0.99%) $913.65
(0.02%) $0.934
(0.76%) $10.99
(-0.10%) $0.802
(-0.98%) $92.28
-20.00% $ 0.00400
Live Chart Being Loaded With Signals
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries...
Stats | |
---|---|
Today's Volume | 3.22M |
Average Volume | 4.60M |
Market Cap | 10.14M |
EPS | $0 ( 2024-02-27 ) |
Last Dividend | $0.00878 ( 1997-05-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Avecho Biotechnology Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Avecho Biotechnology Ltd Financials
Annual | 2023 |
Revenue: | $473 551 |
Gross Profit: | $-222 490 (-46.98 %) |
EPS: | $-0.00150 |
Q4 | 2023 |
Revenue: | $27 112.00 |
Gross Profit: | $-436 282 (-1 609.18 %) |
EPS: | $-0.000400 |
Q2 | 2023 |
Revenue: | $446 439 |
Gross Profit: | $213 792 (47.89 %) |
EPS: | $-0.00110 |
Q4 | 2022 |
Revenue: | $371 021 |
Gross Profit: | $235 976 (63.60 %) |
EPS: | $-0.000900 |
Financial Reports:
No articles found.
Avecho Biotechnology Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00878 | 1997-05-19 |
Last Dividend | $0.00878 | 1997-05-19 |
Next Dividend | $0 | N/A |
Payout Date | 1997-06-06 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.00878 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MXT.AX | Ex Dividend Knight | 2023-08-31 | Monthly | 0 | 0.00% | |
WBC.AX | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
EHL.AX | Ex Dividend Knight | 2023-09-07 | Sporadic | 0 | 0.00% | |
PCG.AX | Ex Dividend Junior | 2023-08-29 | Annually | 0 | 0.00% | |
ALU.AX | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
GUD.AX | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
RFF.AX | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
BRG.AX | Ex Dividend Knight | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
KSL.AX | Ex Dividend Knight | 2023-09-06 | Semi-Annually | 0 | 0.00% | |
SRV.AX | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -7.26 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.470 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.802 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.30 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.83 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.53 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0239 | -1.500 | 9.60 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -298.85 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.000669 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000502 | -0.00100 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.470 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.69 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -18.16 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0647 | 0.800 | -2.90 | -2.32 | [0.5 - 2] |
Total Score | -2.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.69 | 1.000 | -0.474 | 0 | [1 - 100] |
returnOnEquityTTM | -0.802 | 2.50 | -6.44 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.00100 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00100 | 2.00 | -0.000334 | -0.000669 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0339 | 1.500 | -3.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -6.72 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.58 |
Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators